| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 67 | 2020 | 693 | 9.060 |
Why?
|
| Coronary Artery Disease | 56 | 2019 | 359 | 8.150 |
Why?
|
| Cardiovascular Diseases | 51 | 2019 | 1013 | 4.680 |
Why?
|
| Coronary Disease | 31 | 2018 | 200 | 3.910 |
Why?
|
| Estrogen Replacement Therapy | 29 | 2010 | 182 | 3.880 |
Why?
|
| Ethnic Groups | 39 | 2020 | 440 | 3.830 |
Why?
|
| Aged | 178 | 2020 | 9487 | 3.350 |
Why?
|
| C-Reactive Protein | 27 | 2016 | 232 | 3.310 |
Why?
|
| Middle Aged | 184 | 2020 | 10829 | 3.240 |
Why?
|
| Endothelium, Vascular | 21 | 2019 | 145 | 3.100 |
Why?
|
| Female | 218 | 2020 | 18164 | 3.010 |
Why?
|
| Risk Factors | 101 | 2020 | 3531 | 3.010 |
Why?
|
| Postmenopause | 36 | 2019 | 397 | 2.890 |
Why?
|
| Vasodilation | 21 | 2019 | 87 | 2.840 |
Why?
|
| Brachial Artery | 24 | 2019 | 66 | 2.680 |
Why?
|
| Humans | 251 | 2020 | 29093 | 2.620 |
Why?
|
| Polymorphism, Single Nucleotide | 36 | 2019 | 1079 | 2.600 |
Why?
|
| Risk Assessment | 46 | 2020 | 1305 | 2.580 |
Why?
|
| Male | 169 | 2020 | 17807 | 2.450 |
Why?
|
| Heart Failure | 18 | 2020 | 568 | 2.350 |
Why?
|
| Aged, 80 and over | 82 | 2020 | 3717 | 2.220 |
Why?
|
| Coronary Vessels | 17 | 2019 | 147 | 2.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2020 | 126 | 2.060 |
Why?
|
| Myocardial Infarction | 21 | 2020 | 412 | 1.970 |
Why?
|
| Asian Americans | 16 | 2019 | 98 | 1.960 |
Why?
|
| Carotid Artery Diseases | 11 | 2019 | 109 | 1.940 |
Why?
|
| Prospective Studies | 44 | 2020 | 2019 | 1.800 |
Why?
|
| Cohort Studies | 48 | 2020 | 1687 | 1.800 |
Why?
|
| Diabetes Mellitus, Type 2 | 32 | 2019 | 1379 | 1.760 |
Why?
|
| Aortic Diseases | 5 | 2018 | 54 | 1.740 |
Why?
|
| Coronary Angiography | 16 | 2019 | 136 | 1.720 |
Why?
|
| Electrocardiography | 18 | 2020 | 562 | 1.710 |
Why?
|
| Follow-Up Studies | 43 | 2020 | 2108 | 1.590 |
Why?
|
| Stroke Volume | 11 | 2019 | 278 | 1.580 |
Why?
|
| United States | 58 | 2020 | 3630 | 1.560 |
Why?
|
| Hypertension | 15 | 2020 | 906 | 1.530 |
Why?
|
| Atrial Fibrillation | 5 | 2020 | 311 | 1.510 |
Why?
|
| Incidence | 36 | 2020 | 1119 | 1.500 |
Why?
|
| Predictive Value of Tests | 28 | 2020 | 787 | 1.460 |
Why?
|
| European Continental Ancestry Group | 35 | 2020 | 1131 | 1.440 |
Why?
|
| Estrogens | 13 | 2007 | 162 | 1.370 |
Why?
|
| Receptors, Estrogen | 6 | 2010 | 89 | 1.300 |
Why?
|
| Chest Pain | 9 | 2020 | 175 | 1.280 |
Why?
|
| Proportional Hazards Models | 27 | 2019 | 709 | 1.280 |
Why?
|
| Prognosis | 26 | 2020 | 1362 | 1.270 |
Why?
|
| Estrogens, Conjugated (USP) | 15 | 2010 | 125 | 1.270 |
Why?
|
| Cholesterol | 7 | 2016 | 229 | 1.250 |
Why?
|
| Polymorphism, Genetic | 12 | 2013 | 196 | 1.190 |
Why?
|
| Genome-Wide Association Study | 13 | 2019 | 543 | 1.160 |
Why?
|
| Blood Glucose | 11 | 2017 | 466 | 1.150 |
Why?
|
| Hispanic Americans | 23 | 2020 | 904 | 1.150 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2019 | 836 | 1.100 |
Why?
|
| Adult | 55 | 2020 | 8420 | 1.090 |
Why?
|
| Blood Pressure | 14 | 2017 | 804 | 1.070 |
Why?
|
| Stroke | 13 | 2018 | 545 | 1.070 |
Why?
|
| Calcinosis | 10 | 2016 | 143 | 1.040 |
Why?
|
| American Heart Association | 9 | 2016 | 84 | 1.010 |
Why?
|
| Metabolomics | 6 | 2020 | 45 | 0.990 |
Why?
|
| Medroxyprogesterone Acetate | 10 | 2009 | 89 | 0.980 |
Why?
|
| Genetic Variation | 8 | 2019 | 251 | 0.950 |
Why?
|
| Cholesterol, HDL | 8 | 2019 | 165 | 0.890 |
Why?
|
| Aorta | 3 | 2018 | 103 | 0.880 |
Why?
|
| Proteomics | 4 | 2020 | 92 | 0.870 |
Why?
|
| Magnetic Resonance Imaging, Cine | 4 | 2018 | 64 | 0.860 |
Why?
|
| Pharmacogenetics | 6 | 2014 | 35 | 0.840 |
Why?
|
| Ankle Brachial Index | 5 | 2019 | 37 | 0.830 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2020 | 57 | 0.830 |
Why?
|
| Prevalence | 20 | 2019 | 896 | 0.820 |
Why?
|
| Carotid Arteries | 8 | 2016 | 97 | 0.820 |
Why?
|
| Ventricular Function, Left | 5 | 2016 | 194 | 0.810 |
Why?
|
| African Americans | 24 | 2020 | 1373 | 0.810 |
Why?
|
| Ultrasonography | 18 | 2019 | 345 | 0.800 |
Why?
|
| Diet | 7 | 2020 | 354 | 0.790 |
Why?
|
| Genome, Human | 5 | 2014 | 129 | 0.790 |
Why?
|
| Time Factors | 19 | 2020 | 2001 | 0.790 |
Why?
|
| Disease Progression | 19 | 2019 | 572 | 0.780 |
Why?
|
| Calcium | 9 | 2019 | 296 | 0.770 |
Why?
|
| Hormone Replacement Therapy | 5 | 2004 | 86 | 0.770 |
Why?
|
| Case-Control Studies | 16 | 2019 | 859 | 0.760 |
Why?
|
| Cross-Sectional Studies | 24 | 2020 | 1356 | 0.750 |
Why?
|
| Multivariate Analysis | 12 | 2014 | 637 | 0.740 |
Why?
|
| Acute Coronary Syndrome | 5 | 2020 | 175 | 0.730 |
Why?
|
| Atrial Premature Complexes | 1 | 2020 | 15 | 0.730 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2005 | 29 | 0.730 |
Why?
|
| Hypertrophy, Left Ventricular | 4 | 2016 | 105 | 0.730 |
Why?
|
| Fatty Acids, Omega-3 | 4 | 2019 | 52 | 0.710 |
Why?
|
| Proteins | 2 | 2018 | 140 | 0.710 |
Why?
|
| Antihypertensive Agents | 4 | 2015 | 339 | 0.700 |
Why?
|
| Seafood | 3 | 2010 | 11 | 0.700 |
Why?
|
| Hospitals, University | 1 | 2019 | 23 | 0.690 |
Why?
|
| DNA Methylation | 7 | 2017 | 130 | 0.680 |
Why?
|
| Interleukin-6 | 9 | 2014 | 225 | 0.670 |
Why?
|
| Severity of Illness Index | 16 | 2019 | 863 | 0.670 |
Why?
|
| Diabetes Complications | 5 | 2014 | 171 | 0.660 |
Why?
|
| Lipoproteins | 5 | 2010 | 82 | 0.660 |
Why?
|
| Fibroblast Growth Factors | 1 | 2018 | 34 | 0.660 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 374 | 0.650 |
Why?
|
| Phenotype | 13 | 2019 | 629 | 0.650 |
Why?
|
| Primary Prevention | 2 | 2016 | 47 | 0.650 |
Why?
|
| Disease Management | 1 | 2019 | 114 | 0.650 |
Why?
|
| Hemorheology | 3 | 2007 | 7 | 0.640 |
Why?
|
| Linear Models | 11 | 2019 | 426 | 0.630 |
Why?
|
| Arteries | 8 | 2013 | 60 | 0.630 |
Why?
|
| African Continental Ancestry Group | 11 | 2017 | 350 | 0.630 |
Why?
|
| Dietary Supplements | 3 | 2010 | 170 | 0.610 |
Why?
|
| Scavenger Receptors, Class B | 5 | 2018 | 12 | 0.590 |
Why?
|
| Tunica Intima | 7 | 2011 | 59 | 0.590 |
Why?
|
| Alcohol Drinking | 1 | 2019 | 244 | 0.580 |
Why?
|
| Family Health | 2 | 2016 | 78 | 0.560 |
Why?
|
| Age Factors | 13 | 2020 | 1108 | 0.560 |
Why?
|
| Inflammation | 8 | 2014 | 507 | 0.550 |
Why?
|
| Clinical Trials as Topic | 3 | 2013 | 298 | 0.550 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2016 | 136 | 0.540 |
Why?
|
| Emigrants and Immigrants | 3 | 2016 | 235 | 0.540 |
Why?
|
| Genotype | 21 | 2017 | 735 | 0.540 |
Why?
|
| Triglycerides | 11 | 2019 | 214 | 0.530 |
Why?
|
| Cardiology | 2 | 2015 | 72 | 0.520 |
Why?
|
| Tamoxifen | 3 | 2005 | 48 | 0.520 |
Why?
|
| Odds Ratio | 11 | 2020 | 447 | 0.520 |
Why?
|
| Carotid Artery, Common | 3 | 2019 | 37 | 0.520 |
Why?
|
| Monocytes | 5 | 2017 | 119 | 0.510 |
Why?
|
| Sex Characteristics | 3 | 2020 | 167 | 0.510 |
Why?
|
| Emergency Service, Hospital | 8 | 2020 | 430 | 0.510 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2014 | 12 | 0.510 |
Why?
|
| Carotid Artery, Internal | 2 | 2012 | 29 | 0.500 |
Why?
|
| Atrial Function, Left | 1 | 2014 | 18 | 0.500 |
Why?
|
| Prediabetic State | 3 | 2019 | 54 | 0.490 |
Why?
|
| Alleles | 9 | 2017 | 251 | 0.490 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2014 | 9 | 0.490 |
Why?
|
| Double-Blind Method | 15 | 2010 | 501 | 0.490 |
Why?
|
| Coronary Stenosis | 2 | 2004 | 28 | 0.490 |
Why?
|
| Heart Atria | 1 | 2014 | 62 | 0.480 |
Why?
|
| Postural Balance | 2 | 2016 | 160 | 0.480 |
Why?
|
| Cholesterol, LDL | 8 | 2019 | 157 | 0.470 |
Why?
|
| Aorta, Thoracic | 3 | 2011 | 72 | 0.460 |
Why?
|
| Leg | 6 | 2006 | 56 | 0.460 |
Why?
|
| Pesticides | 2 | 2016 | 189 | 0.460 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2011 | 27 | 0.460 |
Why?
|
| Occupational Exposure | 2 | 2016 | 224 | 0.450 |
Why?
|
| Dietary Fats | 3 | 2014 | 108 | 0.450 |
Why?
|
| Heart Failure, Systolic | 1 | 2012 | 12 | 0.450 |
Why?
|
| Arginine | 2 | 2003 | 17 | 0.440 |
Why?
|
| Transients and Migrants | 2 | 2016 | 281 | 0.440 |
Why?
|
| E-Selectin | 4 | 2013 | 20 | 0.430 |
Why?
|
| Reproducibility of Results | 13 | 2018 | 726 | 0.430 |
Why?
|
| North Carolina | 10 | 2020 | 1423 | 0.430 |
Why?
|
| Estrogen Receptor alpha | 6 | 2010 | 50 | 0.430 |
Why?
|
| Genomics | 4 | 2015 | 82 | 0.430 |
Why?
|
| Intercellular Adhesion Molecule-1 | 5 | 2014 | 41 | 0.420 |
Why?
|
| Carotid Stenosis | 1 | 2012 | 56 | 0.410 |
Why?
|
| Snoring | 1 | 2011 | 8 | 0.410 |
Why?
|
| Lipid Metabolism | 2 | 2018 | 100 | 0.410 |
Why?
|
| Progestins | 3 | 2006 | 18 | 0.400 |
Why?
|
| Smoking | 5 | 2018 | 427 | 0.400 |
Why?
|
| Young Adult | 8 | 2019 | 2402 | 0.400 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2019 | 1218 | 0.400 |
Why?
|
| Longitudinal Studies | 10 | 2020 | 720 | 0.400 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 45 | 0.390 |
Why?
|
| Regional Blood Flow | 6 | 2010 | 82 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2006 | 464 | 0.390 |
Why?
|
| Diabetic Angiopathies | 5 | 2015 | 137 | 0.390 |
Why?
|
| Flavonoids | 1 | 2010 | 18 | 0.390 |
Why?
|
| Phenols | 1 | 2010 | 16 | 0.390 |
Why?
|
| Vitis | 1 | 2010 | 12 | 0.390 |
Why?
|
| Arteriosclerosis | 4 | 2005 | 116 | 0.380 |
Why?
|
| Venous Thrombosis | 2 | 2019 | 48 | 0.380 |
Why?
|
| Venous Thromboembolism | 1 | 2010 | 25 | 0.380 |
Why?
|
| Dietary Carbohydrates | 2 | 2014 | 21 | 0.380 |
Why?
|
| Sex Factors | 11 | 2020 | 631 | 0.370 |
Why?
|
| Dietary Fiber | 2 | 2007 | 19 | 0.370 |
Why?
|
| Exercise Tolerance | 4 | 2013 | 110 | 0.370 |
Why?
|
| Software | 4 | 2020 | 109 | 0.370 |
Why?
|
| Plant Extracts | 1 | 2010 | 60 | 0.370 |
Why?
|
| Heart Rate | 3 | 2020 | 315 | 0.360 |
Why?
|
| Heart Ventricles | 3 | 2017 | 107 | 0.360 |
Why?
|
| Antioxidants | 1 | 2010 | 114 | 0.360 |
Why?
|
| Hospitalization | 4 | 2020 | 417 | 0.350 |
Why?
|
| Diabetes Mellitus | 6 | 2016 | 366 | 0.350 |
Why?
|
| Heptanoic Acids | 4 | 2014 | 28 | 0.350 |
Why?
|
| Body Mass Index | 10 | 2019 | 865 | 0.350 |
Why?
|
| Asian Continental Ancestry Group | 7 | 2013 | 110 | 0.350 |
Why?
|
| Treatment Outcome | 15 | 2018 | 3099 | 0.340 |
Why?
|
| Pyrroles | 4 | 2014 | 55 | 0.340 |
Why?
|
| Platelet Aggregation | 3 | 2003 | 21 | 0.340 |
Why?
|
| Troponin | 5 | 2020 | 79 | 0.330 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2014 | 79 | 0.330 |
Why?
|
| Comorbidity | 9 | 2014 | 540 | 0.330 |
Why?
|
| Critical Pathways | 3 | 2018 | 49 | 0.330 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 101 | 0.330 |
Why?
|
| Aging | 5 | 2015 | 881 | 0.330 |
Why?
|
| Cause of Death | 5 | 2017 | 220 | 0.320 |
Why?
|
| Patient Discharge | 3 | 2019 | 168 | 0.320 |
Why?
|
| Vascular Resistance | 2 | 2004 | 28 | 0.310 |
Why?
|
| Mortality | 2 | 2020 | 109 | 0.310 |
Why?
|
| Survival Analysis | 5 | 2016 | 440 | 0.310 |
Why?
|
| Confidence Intervals | 4 | 2015 | 140 | 0.310 |
Why?
|
| Interleukin-10 | 1 | 2007 | 30 | 0.310 |
Why?
|
| Algorithms | 7 | 2020 | 462 | 0.310 |
Why?
|
| Albuminuria | 2 | 2008 | 176 | 0.300 |
Why?
|
| Hyperemia | 1 | 2007 | 10 | 0.300 |
Why?
|
| Survival Rate | 8 | 2019 | 795 | 0.300 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2007 | 14 | 0.300 |
Why?
|
| Contraceptive Agents, Female | 1 | 2007 | 15 | 0.300 |
Why?
|
| Sensitivity and Specificity | 6 | 2020 | 532 | 0.300 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 2006 | 6 | 0.300 |
Why?
|
| Adolescent | 8 | 2019 | 3254 | 0.300 |
Why?
|
| Heart Diseases | 3 | 2016 | 97 | 0.300 |
Why?
|
| Genetic Loci | 4 | 2019 | 147 | 0.290 |
Why?
|
| Uric Acid | 1 | 2006 | 24 | 0.290 |
Why?
|
| Reference Values | 9 | 2016 | 224 | 0.290 |
Why?
|
| Membrane Proteins | 2 | 2006 | 256 | 0.270 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2005 | 11 | 0.270 |
Why?
|
| Fatty Acid Desaturases | 2 | 2017 | 44 | 0.270 |
Why?
|
| Analysis of Variance | 5 | 2016 | 454 | 0.270 |
Why?
|
| Multicenter Studies as Topic | 6 | 2016 | 92 | 0.270 |
Why?
|
| Hypercholesterolemia | 2 | 2003 | 59 | 0.270 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 2006 | 26 | 0.270 |
Why?
|
| Thromboembolism | 2 | 2002 | 30 | 0.270 |
Why?
|
| Sex Distribution | 4 | 2016 | 186 | 0.260 |
Why?
|
| Autopsy | 2 | 2018 | 37 | 0.260 |
Why?
|
| Systems Biology | 2 | 2014 | 9 | 0.250 |
Why?
|
| Tunica Media | 4 | 2011 | 29 | 0.250 |
Why?
|
| Models, Biological | 3 | 2016 | 373 | 0.250 |
Why?
|
| Retrospective Studies | 7 | 2019 | 3111 | 0.250 |
Why?
|
| Age Distribution | 4 | 2016 | 198 | 0.250 |
Why?
|
| Matrix Metalloproteinases | 1 | 2003 | 9 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2019 | 871 | 0.240 |
Why?
|
| Repressor Proteins | 2 | 2015 | 53 | 0.240 |
Why?
|
| Fasting | 4 | 2014 | 93 | 0.230 |
Why?
|
| DNA | 5 | 2014 | 204 | 0.230 |
Why?
|
| Food, Fortified | 1 | 2003 | 5 | 0.230 |
Why?
|
| Retinal Vessels | 2 | 2015 | 18 | 0.230 |
Why?
|
| ROC Curve | 6 | 2014 | 149 | 0.220 |
Why?
|
| Logistic Models | 7 | 2020 | 727 | 0.220 |
Why?
|
| Factor V | 1 | 2002 | 6 | 0.220 |
Why?
|
| Diagnostic Imaging | 3 | 2016 | 88 | 0.220 |
Why?
|
| Renin-Angiotensin System | 1 | 2004 | 182 | 0.220 |
Why?
|
| Insulin Resistance | 4 | 2014 | 449 | 0.220 |
Why?
|
| San Francisco | 2 | 2019 | 4 | 0.210 |
Why?
|
| Chicago | 2 | 2019 | 8 | 0.210 |
Why?
|
| Intra-Abdominal Fat | 2 | 2019 | 61 | 0.210 |
Why?
|
| Elasticity | 3 | 2011 | 34 | 0.210 |
Why?
|
| Haplotypes | 4 | 2010 | 220 | 0.200 |
Why?
|
| Exercise Test | 4 | 2012 | 194 | 0.200 |
Why?
|
| Insulin | 2 | 2014 | 346 | 0.200 |
Why?
|
| Risk | 7 | 2016 | 289 | 0.200 |
Why?
|
| Lipoproteins, HDL | 2 | 2017 | 247 | 0.200 |
Why?
|
| Women's Health | 4 | 2007 | 226 | 0.200 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2019 | 26 | 0.200 |
Why?
|
| Gene Expression | 3 | 2020 | 332 | 0.190 |
Why?
|
| Continental Population Groups | 3 | 2019 | 221 | 0.190 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2013 | 65 | 0.190 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2017 | 23 | 0.190 |
Why?
|
| Socioeconomic Factors | 3 | 2019 | 391 | 0.190 |
Why?
|
| Chi-Square Distribution | 4 | 2014 | 293 | 0.180 |
Why?
|
| Computational Biology | 2 | 2011 | 86 | 0.180 |
Why?
|
| Feeding Behavior | 2 | 2015 | 159 | 0.180 |
Why?
|
| Thiazolidinediones | 2 | 2010 | 47 | 0.180 |
Why?
|
| Blood Flow Velocity | 3 | 2010 | 59 | 0.180 |
Why?
|
| Autonomic Nervous System | 1 | 2020 | 42 | 0.180 |
Why?
|
| Probability | 6 | 2011 | 150 | 0.180 |
Why?
|
| Research Design | 4 | 2013 | 286 | 0.180 |
Why?
|
| India | 3 | 2016 | 61 | 0.180 |
Why?
|
| Epidemiology | 1 | 2019 | 5 | 0.180 |
Why?
|
| Transcription Factors | 2 | 2017 | 172 | 0.180 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2019 | 28 | 0.170 |
Why?
|
| Health Status | 4 | 2020 | 368 | 0.170 |
Why?
|
| Chromosome Mapping | 2 | 2017 | 190 | 0.170 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 33 | 0.170 |
Why?
|
| Heart | 1 | 2020 | 161 | 0.170 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2018 | 9 | 0.170 |
Why?
|
| Seeds | 2 | 2010 | 9 | 0.170 |
Why?
|
| Hypoglycemic Agents | 2 | 2010 | 176 | 0.170 |
Why?
|
| Animals | 8 | 2016 | 7297 | 0.160 |
Why?
|
| Pedigree | 3 | 2010 | 133 | 0.160 |
Why?
|
| Models, Genetic | 3 | 2019 | 92 | 0.160 |
Why?
|
| Decision Support Techniques | 2 | 2020 | 104 | 0.160 |
Why?
|
| Gene Frequency | 4 | 2011 | 225 | 0.160 |
Why?
|
| Aorta, Abdominal | 2 | 2011 | 26 | 0.160 |
Why?
|
| Oxidative Stress | 3 | 2014 | 223 | 0.160 |
Why?
|
| Obesity | 3 | 2015 | 1063 | 0.160 |
Why?
|
| Long QT Syndrome | 2 | 2009 | 39 | 0.160 |
Why?
|
| Cardiovascular System | 3 | 2010 | 39 | 0.160 |
Why?
|
| Blood Pressure Determination | 2 | 2017 | 94 | 0.160 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2014 | 14 | 0.160 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 113 | 0.160 |
Why?
|
| Hospital Mortality | 1 | 2019 | 186 | 0.160 |
Why?
|
| Mutation | 4 | 2014 | 466 | 0.160 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 43 | 0.160 |
Why?
|
| Rest | 2 | 2016 | 49 | 0.160 |
Why?
|
| Cross-Over Studies | 2 | 2010 | 94 | 0.160 |
Why?
|
| Registries | 1 | 2019 | 278 | 0.150 |
Why?
|
| Multigene Family | 1 | 2017 | 47 | 0.150 |
Why?
|
| Compliance | 4 | 2005 | 12 | 0.150 |
Why?
|
| Plethysmography | 4 | 2005 | 13 | 0.150 |
Why?
|
| Metabolome | 1 | 2017 | 31 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 2 | 2016 | 103 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 73 | 0.150 |
Why?
|
| Body Composition | 1 | 2019 | 365 | 0.150 |
Why?
|
| Troponin C | 1 | 2017 | 9 | 0.150 |
Why?
|
| Erectile Dysfunction | 1 | 2017 | 48 | 0.150 |
Why?
|
| Age of Onset | 3 | 2014 | 95 | 0.150 |
Why?
|
| Brain Ischemia | 2 | 2012 | 136 | 0.150 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 142 | 0.150 |
Why?
|
| Choristoma | 1 | 2016 | 17 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2008 | 36 | 0.150 |
Why?
|
| Carrier Proteins | 1 | 2017 | 131 | 0.140 |
Why?
|
| Placebos | 4 | 2010 | 61 | 0.140 |
Why?
|
| Natriuretic Peptide, C-Type | 1 | 2016 | 1 | 0.140 |
Why?
|
| Parity | 2 | 2014 | 12 | 0.140 |
Why?
|
| Physical Conditioning, Animal | 1 | 2016 | 32 | 0.140 |
Why?
|
| Cognition | 1 | 2020 | 526 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 546 | 0.140 |
Why?
|
| Lipids | 2 | 2009 | 209 | 0.140 |
Why?
|
| Genetics, Population | 2 | 2014 | 30 | 0.140 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2015 | 7 | 0.140 |
Why?
|
| Health Status Indicators | 1 | 2016 | 67 | 0.140 |
Why?
|
| Asia | 3 | 2020 | 17 | 0.130 |
Why?
|
| Resorcinols | 1 | 2015 | 6 | 0.130 |
Why?
|
| Anticholesteremic Agents | 2 | 2007 | 36 | 0.130 |
Why?
|
| Microvessels | 1 | 2015 | 23 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2006 | 134 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 39 | 0.130 |
Why?
|
| Mutation, Missense | 1 | 2015 | 48 | 0.130 |
Why?
|
| Cardiology Service, Hospital | 1 | 2015 | 22 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2016 | 190 | 0.130 |
Why?
|
| Genes, cdc | 1 | 2014 | 4 | 0.130 |
Why?
|
| Apolipoproteins A | 1 | 2014 | 25 | 0.130 |
Why?
|
| Simvastatin | 1 | 2014 | 25 | 0.130 |
Why?
|
| Models, Cardiovascular | 2 | 2016 | 27 | 0.130 |
Why?
|
| Life Expectancy | 1 | 2014 | 16 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 47 | 0.130 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 35 | 0.130 |
Why?
|
| Anthracyclines | 1 | 2014 | 51 | 0.120 |
Why?
|
| Receptors, LDL | 1 | 2014 | 64 | 0.120 |
Why?
|
| Ischemic Attack, Transient | 1 | 2014 | 46 | 0.120 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 52 | 0.120 |
Why?
|
| Drug Therapy, Combination | 4 | 2010 | 273 | 0.120 |
Why?
|
| Ultrasonography, Doppler | 2 | 2012 | 18 | 0.120 |
Why?
|
| Decision Making | 1 | 2016 | 180 | 0.120 |
Why?
|
| Genetics | 1 | 2013 | 4 | 0.120 |
Why?
|
| Endpoint Determination | 1 | 2013 | 19 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 384 | 0.120 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 28 | 0.120 |
Why?
|
| Databases, Genetic | 1 | 2013 | 35 | 0.120 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2013 | 6 | 0.120 |
Why?
|
| Body Surface Potential Mapping | 1 | 2013 | 12 | 0.120 |
Why?
|
| Genetic Markers | 1 | 2014 | 122 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2016 | 327 | 0.120 |
Why?
|
| Lipoproteins, LDL | 1 | 2014 | 77 | 0.120 |
Why?
|
| Nitric Oxide | 3 | 2003 | 116 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 1 | 2013 | 29 | 0.120 |
Why?
|
| Fixatives | 1 | 2013 | 3 | 0.120 |
Why?
|
| Paraffin | 1 | 2013 | 4 | 0.120 |
Why?
|
| Paraffin Embedding | 1 | 2013 | 10 | 0.120 |
Why?
|
| Fishes | 2 | 2010 | 7 | 0.120 |
Why?
|
| Formaldehyde | 1 | 2013 | 11 | 0.120 |
Why?
|
| Medroxyprogesterone | 3 | 2010 | 12 | 0.110 |
Why?
|
| von Willebrand Factor | 1 | 2013 | 17 | 0.110 |
Why?
|
| Tomography, Spiral Computed | 1 | 2013 | 18 | 0.110 |
Why?
|
| Life Style | 2 | 2014 | 364 | 0.110 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2013 | 46 | 0.110 |
Why?
|
| Menopause, Premature | 1 | 2012 | 8 | 0.110 |
Why?
|
| Trans Fatty Acids | 1 | 2012 | 10 | 0.110 |
Why?
|
| Air Pollution | 1 | 2012 | 17 | 0.110 |
Why?
|
| Air Pollutants | 1 | 2012 | 20 | 0.110 |
Why?
|
| Particulate Matter | 1 | 2012 | 30 | 0.110 |
Why?
|
| Policy Making | 1 | 2012 | 19 | 0.110 |
Why?
|
| Diet Surveys | 2 | 2015 | 56 | 0.110 |
Why?
|
| Estradiol | 2 | 2019 | 118 | 0.110 |
Why?
|
| Fibrinogen | 2 | 2009 | 42 | 0.110 |
Why?
|
| Myocardial Ischemia | 3 | 2012 | 83 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2011 | 13 | 0.110 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2017 | 59 | 0.100 |
Why?
|
| Menopause | 1 | 2012 | 86 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 281 | 0.100 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2011 | 35 | 0.100 |
Why?
|
| CpG Islands | 3 | 2017 | 44 | 0.100 |
Why?
|
| Ultrasonography, Interventional | 2 | 2012 | 51 | 0.100 |
Why?
|
| Acute Disease | 2 | 2020 | 239 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 72 | 0.100 |
Why?
|
| Estrogen Receptor beta | 1 | 2010 | 12 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2013 | 229 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2011 | 207 | 0.100 |
Why?
|
| Phospholipids | 1 | 2010 | 26 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 287 | 0.100 |
Why?
|
| Epigenesis, Genetic | 3 | 2017 | 98 | 0.090 |
Why?
|
| Sphingomyelins | 1 | 2009 | 7 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2017 | 320 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 139 | 0.090 |
Why?
|
| Radiography | 2 | 2011 | 353 | 0.090 |
Why?
|
| Single-Blind Method | 2 | 2013 | 165 | 0.090 |
Why?
|
| Entropy | 1 | 2009 | 8 | 0.090 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2009 | 4 | 0.090 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2009 | 11 | 0.090 |
Why?
|
| Lipoprotein Lipase | 1 | 2009 | 14 | 0.090 |
Why?
|
| Genome | 1 | 2009 | 40 | 0.090 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2009 | 5 | 0.090 |
Why?
|
| Lipase | 1 | 2009 | 28 | 0.090 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2009 | 3 | 0.090 |
Why?
|
| KCNQ1 Potassium Channel | 1 | 2009 | 9 | 0.090 |
Why?
|
| Sodium Channels | 1 | 2009 | 13 | 0.090 |
Why?
|
| Hormones | 1 | 2008 | 19 | 0.090 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 60 | 0.090 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 17 | 0.090 |
Why?
|
| Glucose Intolerance | 1 | 2009 | 44 | 0.080 |
Why?
|
| Kidney Diseases | 1 | 2011 | 239 | 0.080 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2019 | 20 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2009 | 57 | 0.080 |
Why?
|
| Drug Interactions | 3 | 2005 | 80 | 0.080 |
Why?
|
| Epoxide Hydrolases | 1 | 2008 | 5 | 0.080 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2008 | 6 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2008 | 6 | 0.080 |
Why?
|
| Ventricular Fibrillation | 1 | 2008 | 4 | 0.080 |
Why?
|
| Liver | 3 | 2016 | 464 | 0.080 |
Why?
|
| Tachycardia, Ventricular | 1 | 2008 | 14 | 0.080 |
Why?
|
| Quality Control | 2 | 2019 | 38 | 0.080 |
Why?
|
| Oxygen Consumption | 3 | 2013 | 138 | 0.080 |
Why?
|
| Genetic Testing | 2 | 2012 | 90 | 0.080 |
Why?
|
| Vasculitis | 1 | 2007 | 23 | 0.080 |
Why?
|
| Genetics, Medical | 1 | 2007 | 3 | 0.080 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2008 | 59 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2007 | 242 | 0.080 |
Why?
|
| Tourniquets | 1 | 2007 | 11 | 0.080 |
Why?
|
| Kidney | 1 | 2011 | 485 | 0.080 |
Why?
|
| Observation | 1 | 2007 | 23 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 1 | 2007 | 39 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2007 | 13 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2007 | 17 | 0.070 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2006 | 3 | 0.070 |
Why?
|
| Stress, Mechanical | 1 | 2007 | 90 | 0.070 |
Why?
|
| Amlodipine | 1 | 2006 | 14 | 0.070 |
Why?
|
| Docosahexaenoic Acids | 1 | 2006 | 20 | 0.070 |
Why?
|
| Lymphotoxin-alpha | 1 | 2006 | 4 | 0.070 |
Why?
|
| Base Sequence | 2 | 2009 | 240 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 493 | 0.070 |
Why?
|
| Benzazepines | 1 | 2006 | 22 | 0.070 |
Why?
|
| Calcium Channel Blockers | 1 | 2006 | 49 | 0.070 |
Why?
|
| Membrane Glycoproteins | 1 | 2006 | 97 | 0.070 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 30 | 0.070 |
Why?
|
| CD40 Ligand | 1 | 2006 | 13 | 0.070 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2006 | 17 | 0.070 |
Why?
|
| Diabetic Nephropathies | 1 | 2008 | 195 | 0.070 |
Why?
|
| Coronary Circulation | 1 | 2006 | 30 | 0.070 |
Why?
|
| Nuts | 1 | 2005 | 4 | 0.070 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2006 | 47 | 0.070 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2006 | 21 | 0.070 |
Why?
|
| Saphenous Vein | 1 | 2006 | 20 | 0.070 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 148 | 0.070 |
Why?
|
| Exercise | 2 | 2012 | 591 | 0.070 |
Why?
|
| Norpregnenes | 1 | 2005 | 16 | 0.070 |
Why?
|
| Bone Density Conservation Agents | 1 | 2005 | 20 | 0.070 |
Why?
|
| Pakistan | 2 | 2016 | 3 | 0.070 |
Why?
|
| Sri Lanka | 2 | 2016 | 3 | 0.070 |
Why?
|
| Nepal | 2 | 2016 | 9 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2005 | 31 | 0.070 |
Why?
|
| Diuretics | 1 | 2005 | 22 | 0.070 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2005 | 15 | 0.070 |
Why?
|
| Linkage Disequilibrium | 3 | 2014 | 192 | 0.070 |
Why?
|
| Coronary Artery Bypass | 1 | 2006 | 100 | 0.070 |
Why?
|
| Progesterone | 1 | 2005 | 80 | 0.070 |
Why?
|
| Aspirin | 3 | 2016 | 61 | 0.060 |
Why?
|
| Recurrence | 3 | 2014 | 235 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 71 | 0.060 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2019 | 14 | 0.060 |
Why?
|
| Diastole | 2 | 2016 | 90 | 0.060 |
Why?
|
| Cell Cycle | 2 | 2014 | 69 | 0.060 |
Why?
|
| Renal Circulation | 1 | 2004 | 13 | 0.060 |
Why?
|
| Energy Intake | 1 | 2004 | 120 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2003 | 82 | 0.060 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2003 | 10 | 0.060 |
Why?
|
| Behavior | 1 | 2003 | 29 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2003 | 106 | 0.060 |
Why?
|
| Quality of Life | 2 | 2013 | 816 | 0.060 |
Why?
|
| Prodrugs | 1 | 2003 | 13 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2017 | 369 | 0.060 |
Why?
|
| Echocardiography | 2 | 2017 | 140 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 212 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2003 | 96 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 42 | 0.050 |
Why?
|
| Nitric Oxide Synthase | 1 | 2002 | 36 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2002 | 37 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2004 | 279 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 125 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2002 | 103 | 0.050 |
Why?
|
| Angiotensin I | 1 | 2004 | 262 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2002 | 169 | 0.050 |
Why?
|
| Demography | 2 | 2017 | 104 | 0.050 |
Why?
|
| Health Behavior | 2 | 2019 | 214 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2003 | 208 | 0.050 |
Why?
|
| Gene Expression Regulation | 2 | 2015 | 481 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2003 | 149 | 0.050 |
Why?
|
| alpha-Linolenic Acid | 2 | 2014 | 11 | 0.050 |
Why?
|
| Netherlands | 1 | 2020 | 21 | 0.050 |
Why?
|
| Diet Records | 1 | 2020 | 31 | 0.050 |
Why?
|
| Bayes Theorem | 2 | 2011 | 67 | 0.050 |
Why?
|
| Hemodynamics | 2 | 2016 | 148 | 0.050 |
Why?
|
| Regression Analysis | 3 | 2006 | 274 | 0.050 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 42 | 0.050 |
Why?
|
| Emigration and Immigration | 1 | 2020 | 32 | 0.050 |
Why?
|
| Dehydroepiandrosterone | 1 | 2019 | 10 | 0.040 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2019 | 4 | 0.040 |
Why?
|
| Gluconeogenesis | 1 | 2019 | 5 | 0.040 |
Why?
|
| Glutamine | 1 | 2019 | 6 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2019 | 24 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2019 | 11 | 0.040 |
Why?
|
| Glycolysis | 1 | 2019 | 19 | 0.040 |
Why?
|
| Androgens | 1 | 2019 | 22 | 0.040 |
Why?
|
| Methyltransferases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2019 | 20 | 0.040 |
Why?
|
| Mental Health | 1 | 2020 | 104 | 0.040 |
Why?
|
| Amino Acids | 1 | 2019 | 41 | 0.040 |
Why?
|
| Laboratories | 1 | 2019 | 13 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2019 | 52 | 0.040 |
Why?
|
| Cation Transport Proteins | 1 | 2019 | 24 | 0.040 |
Why?
|
| Testosterone | 1 | 2019 | 47 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 196 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 379 | 0.040 |
Why?
|
| Memory | 1 | 2020 | 187 | 0.040 |
Why?
|
| Ohio | 1 | 2018 | 54 | 0.040 |
Why?
|
| Population Surveillance | 2 | 2010 | 119 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2018 | 26 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2010 | 149 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2017 | 9 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 9 | 0.040 |
Why?
|
| Endothelium | 1 | 2017 | 5 | 0.040 |
Why?
|
| Histones | 1 | 2017 | 49 | 0.040 |
Why?
|
| Biological Transport | 1 | 2017 | 62 | 0.040 |
Why?
|
| Bangladesh | 1 | 2016 | 7 | 0.040 |
Why?
|
| Educational Status | 1 | 2017 | 164 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2016 | 20 | 0.040 |
Why?
|
| Workflow | 1 | 2016 | 20 | 0.040 |
Why?
|
| Muscular Diseases | 1 | 2016 | 19 | 0.040 |
Why?
|
| Morbidity | 1 | 2016 | 91 | 0.040 |
Why?
|
| Warfarin | 1 | 2016 | 30 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2016 | 128 | 0.040 |
Why?
|
| Pericardium | 1 | 2016 | 50 | 0.040 |
Why?
|
| Alcoholism | 1 | 2017 | 95 | 0.040 |
Why?
|
| Liver Diseases | 1 | 2016 | 61 | 0.040 |
Why?
|
| Mississippi | 1 | 2016 | 24 | 0.040 |
Why?
|
| Genes, Fungal | 1 | 2016 | 4 | 0.040 |
Why?
|
| Yeasts | 1 | 2016 | 6 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 45 | 0.040 |
Why?
|
| Cardiac Output | 2 | 2006 | 32 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2016 | 82 | 0.030 |
Why?
|
| Dogs | 1 | 2016 | 117 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 77 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 133 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 34 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2016 | 120 | 0.030 |
Why?
|
| Ribosomes | 1 | 2015 | 10 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 2015 | 22 | 0.030 |
Why?
|
| Echocardiography, Stress | 1 | 2015 | 22 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 17 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 46 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2016 | 126 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2014 | 18 | 0.030 |
Why?
|
| Heterozygote | 1 | 2014 | 52 | 0.030 |
Why?
|
| China | 1 | 2014 | 44 | 0.030 |
Why?
|
| Autophagy | 1 | 2015 | 53 | 0.030 |
Why?
|
| Germany | 1 | 2014 | 8 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 114 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 85 | 0.030 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2014 | 29 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 641 | 0.030 |
Why?
|
| Brugada Syndrome | 1 | 2014 | 17 | 0.030 |
Why?
|
| Lung | 1 | 2016 | 233 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 155 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2013 | 10 | 0.030 |
Why?
|
| Length of Stay | 1 | 2015 | 292 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2013 | 18 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2013 | 10 | 0.030 |
Why?
|
| Heart Conduction System | 1 | 2014 | 69 | 0.030 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2013 | 13 | 0.030 |
Why?
|
| Angiography | 1 | 2013 | 75 | 0.030 |
Why?
|
| Child | 1 | 2019 | 2219 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 60 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 111 | 0.030 |
Why?
|
| Cytokines | 1 | 2014 | 243 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2012 | 19 | 0.030 |
Why?
|
| Apoptosis | 1 | 2014 | 337 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2013 | 249 | 0.030 |
Why?
|
| Weight Loss | 1 | 2015 | 413 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 494 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2011 | 3 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2011 | 11 | 0.030 |
Why?
|
| Rats | 1 | 2016 | 1604 | 0.030 |
Why?
|
| Pregnancy | 1 | 2014 | 815 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2011 | 44 | 0.030 |
Why?
|
| Automation | 1 | 2011 | 30 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2010 | 20 | 0.020 |
Why?
|
| Vascular Capacitance | 1 | 2010 | 1 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 268 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2010 | 59 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 23 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2010 | 32 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 64 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2009 | 10 | 0.020 |
Why?
|
| Manometry | 1 | 2009 | 19 | 0.020 |
Why?
|
| Body Height | 1 | 2009 | 30 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 110 | 0.020 |
Why?
|
| Brain | 1 | 2016 | 930 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 163 | 0.020 |
Why?
|
| Neoplasms | 1 | 2014 | 610 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 666 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 93 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2008 | 71 | 0.020 |
Why?
|
| American Hospital Association | 1 | 2007 | 2 | 0.020 |
Why?
|
| Societies, Scientific | 1 | 2007 | 12 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2007 | 9 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2006 | 13 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2006 | 35 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2006 | 97 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2006 | 70 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2007 | 143 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2006 | 18 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2006 | 24 | 0.020 |
Why?
|
| Estrone | 1 | 2006 | 7 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2005 | 47 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2006 | 93 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 15 | 0.020 |
Why?
|
| Thigh | 1 | 2005 | 39 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 129 | 0.020 |
Why?
|
| Homozygote | 1 | 2005 | 57 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 32 | 0.020 |
Why?
|
| Cardiotonic Agents | 1 | 2005 | 39 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2005 | 39 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 50 | 0.020 |
Why?
|
| Syndrome | 1 | 2004 | 66 | 0.020 |
Why?
|
| Hostility | 1 | 2003 | 3 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2003 | 40 | 0.010 |
Why?
|
| Heart Arrest | 1 | 2004 | 39 | 0.010 |
Why?
|
| Polysomnography | 1 | 2003 | 32 | 0.010 |
Why?
|
| Spectrum Analysis | 1 | 2003 | 5 | 0.010 |
Why?
|
| Maryland | 1 | 2003 | 26 | 0.010 |
Why?
|
| Pennsylvania | 1 | 2003 | 77 | 0.010 |
Why?
|
| California | 1 | 2003 | 60 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2008 | 518 | 0.010 |
Why?
|
| Urinary Incontinence | 1 | 2003 | 45 | 0.010 |
Why?
|
| Digitalis | 1 | 2002 | 1 | 0.010 |
Why?
|
| Lipoprotein(a) | 1 | 2002 | 10 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2003 | 181 | 0.010 |
Why?
|
| Social Support | 1 | 2003 | 163 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 207 | 0.010 |
Why?
|
| Depression | 1 | 2003 | 380 | 0.010 |
Why?
|